drugset / Trial / NCT03772249
Study of Safety and Tolerability of DCR HBVS
RandomizedSequentialTriple-blindTreatment
Summary
DCR-HBVS will be evaluated for safety and efficacy in healthy volunteers and chronic hepatitis B patients.
Timeline
- Start
- 2018-12-28
- Primary completion
- 2022-07-12
- Completion
- 2022-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 0.1 mg/kg | Subcutaneous |
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 1.5 mg/kg | Subcutaneous |
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 3 mg/kg | Subcutaneous |
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 6 mg/kg | Subcutaneous |
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 12 mg/kg | Subcutaneous |
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 100 mg | Subcutaneous |
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 200 mg | Subcutaneous |
| Subject | XALNESIRAN | Small interfering RNA (siRNA) | 400 mg | Subcutaneous |